Precise prediction model and simplified scoring system for sustained combined response to interferon-α

Table 2 Individual factors of patients with diverse responses at the 24th week after cease of interferon-α therapy

	CR	PR	NR
Sex (M:F)	110:53	163:51	72:25
Age [0-14):(15-24):(25-44):(≥ 45), yr]	3:64:123:5	5:47:148:14	2:21:71:3
ALT [(1-2):(2-3):(3-5):(5-10):(≥ 10), ULN]	7:5:27:75:49	27:41:71:44:31	19:31:31:13:3
AST [(0-1):(1-2):(2-3):(3-5):(5-10):(≥ 10), ULN]	1:22:30:49:43:18	12:76:54:38:24:10	9:50:18:14:6:0
Genotype (A:B:C)	14:96:53	30:101:83	7:15:75
HBV DNA [(5-5.99):(6-6.99):(7-7.99):(8-8.99):(≥ 9), log copies/mL]	21:55:56:26:5	19:65:79:49:2	5:31:37:21:3
Fibrosis staging, S (0:1:2:3:4)	2:54:51:48:8	7:68:71:50:18	1:32:35:16:13
Histology activity index, G (1:2:3:4)	11:71:60:21	22:95:77:20	6:49:32:10
Responses (CR:PR:NR)	163	214	97

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ULN: Upper limit of normal; HBV: Hepatitis B virus; CR: Combined response; PR: Partial response; NR: No response.